Home
MyCare - Patients: View your medical records securely online here.
Log in Learn More

A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP.

Description:

Study of post-myocardial infarction (heart attack) drug to prevent future cardiovascular events using interleukin anti-body to reduce cardiovascular inflammation. Sponsor: Novartis Pharmaceutical.

Active Date: August 22, 2014
Status: Active/Closed to Enrollment
Principal Name: Thomas Stuver, MD
Phone: (585) 922-3536